Merck’s Lipfendra becomes world’s first oral PCSK9 treatment approved by FDA on July 16, 2026 Approved CORALreef trials enlicitide Hypercholesterolemia LDL-C Lipfendra Merck once-daily tablet Oral cavity PCSK9 inhibitor United States Food and Drug Administration +